Ignite Creation Date:
2024-05-06 @ 7:18 PM
Last Modification Date:
2024-10-26 @ 3:04 PM
Study NCT ID:
NCT05964816
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-01
First Post:
2023-07-20
Brief Title:
A Longitudinal Study of the Trajectory of Financial Toxicity and Its Relationship With Symptom Burden in Breast Cancer Patients
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Longitudinal Study of the Trajectory of Financial Toxicity and Its Relationship With Symptom Burden in Breast Cancer Patients
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Breast cancer has become the leading cause of global cancer incidence With the improvement of treatment methods some breast cancer patients have experienced different degrees of financial toxicity which seriously affected the quality of life treatment compliance and treatment outcomes of patients Currently there are some related studies on financial toxicity in breast cancer patients but they are mainly cross-sectional studies lacking the use of validated financial toxicity tools to measure the longitudinal change trajectory of financial toxicity The financial toxicity of breast cancer patients may change dynamically with the treatment stage expenditure and time so it is necessary to conduct a rigorously designed prospective study to explore the trajectory of financial toxicity In addition previous studies have showed that financial toxicity may be associated with anxiety distress pain and overall symptom burden However the relevant evidence is currently limited This study is designed as a prospective longitudinal study to explore the trajectory of financial toxicity and its influencing factors in breast cancer patients in China and to focus on the relationship between symptom burden and financial toxicity which will help clinicians identify potential high-risk populations and provide a new perspective for future intervention programs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None